Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05119036 · ClinicalTrials.gov registry record · NA
Adjuvant Treatment Deintensification After Transoral Surgery for Human Papillomavirus-Positive Squamous Cell Carcinoma
A NA study of HPV Positive Oropharyngeal Squamous Cell Carcinoma and Squamous Cell Carcinoma of the Oropharynx, sponsored by Indiana University.
- Active
- Registry status
- NA
- Development phase
- 83
- Enrollment target
- 2
- Study locations
NCT05119036: Active NA study of HPV Positive Oropharyngeal Squamous Cell Carcinoma and Squamous Cell Carcinoma of the Oropharynx, sponsored by Indiana University.
NCT05119036 is a NA study of HPV Positive Oropharyngeal Squamous Cell Carcinoma and Squamous Cell Carcinoma of the Oropharynx that is active but no longer recruiting, run by Indiana University. The registered enrollment target is 83 participants, roughly in line with the 87-participant average among 16 other HPV Positive Oropharyngeal Squamous Cell Carcinoma trials with a reported enrollment target. The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05119036, a NA study of HPV Positive Oropharyngeal Squamous Cell Carcinoma and Squamous Cell Carcinoma of the Oropharynx, is active but no longer recruiting, sponsored by Indiana University.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 83 participants
- Enrollment target
- 2
- Study locations
Study Summary
Oropharyngeal squamous cell carcinoma (OPSCC), commonly known as throat cancer or tonsil cancer, has seen a dramatic rise in incidence over the last twenty years. There are two types of OPSCC: human papillomavirus-positive (HPV+) and human papillomavirus-negative (HPV-). People with OPSCC, regardless of their type, typically receive standard treatment with a combination of chemotherapy, radiation therapy, and surgery. Due to the intensity of standard treatment, survivors may experience unwanted long-term side effects. The goal of this research study is to see if intensifying (stopping or scaling back) treatment still provides the same, or perhaps even better, results when compared to standard treatment.
Primary Outcome
Time from surgery to first disease recurrence or death from any cause
Conditions Studied
Interventions
- RADIATION 44 doses of radiation
- RADIATION 54 doses of radiation
Study Locations (2)
Indiana
- IU Health Joe and Shelly Schwarz Cancer Center - Carmel
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2022-05-12 |
| Est. Completion | 2026-04 |
| Phase | NA |
What the registry record for NCT05119036 still lists
NCT05119036 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 83 participants, a relatively small participant target, roughly in line with the 87-participant average among 16 other HPV Positive Oropharyngeal Squamous Cell Carcinoma trials with a reported enrollment target.
The record links to 2 conditions, with HPV Positive Oropharyngeal Squamous Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which 44 doses of radiation is the first listed.
NCT05119036 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT05119036 about?
NCT05119036 is a clinical study titled "Adjuvant Treatment Deintensification After Transoral Surgery for Human Papillomavirus-Positive Squamous Cell Carcinoma". Oropharyngeal squamous cell carcinoma (OPSCC), commonly known as throat cancer or tonsil cancer, has seen a dramatic rise in incidence over the last twenty years. There are two types of OPSCC: human papillomavirus-positive (HPV+) and human papillomavirus-negative (HPV-). People with OPSCC, regardles...
What is the current status of trial NCT05119036?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 83 participants. The study started on 2022-05-12. Estimated completion is 2026-04.
What conditions does trial NCT05119036 study?
This clinical trial studies the following conditions: HPV Positive Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Oropharynx.
What interventions are being tested in trial NCT05119036?
The interventions under investigation include: 44 doses of radiation (RADIATION), 54 doses of radiation (RADIATION).
Who is sponsoring clinical trial NCT05119036?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05119036 being conducted?
This trial has 2 study locations across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HPV Positive Oropharyngeal Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05119036's enrollment target sits among peer trials
83 8th of 16 higher than 8 of 16 other HPV Positive Oropharyngeal Squamous Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HPV Positive Oropharyngeal Squamous Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer
RECRUITING · Phase 1
-
A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)
RECRUITING · Phase 2
-
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
RECRUITING · Phase 2
-
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
RECRUITING · Phase 1
-
TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers
RECRUITING · Phase 1
-
Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02974647 · 83 participants · Phase 2
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
- NCT03919292 · 83 participants · Phase 1
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
- NCT04626674 · 83 participants · Phase 1
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
- NCT05277168 · 83 participants · Phase 1
A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI